top of page

GPCR Retreat Program

A positive Allosteric Modulator of M1 Acetylcholine Receptors Improves Cognitive Deficits in Male and Female Alzheimer’s Mice

A positive Allosteric Modulator of M1 Acetylcholine Receptors Improves Cognitive Deficits in Male and Female Alzheimer’s Mice

Date & Time

Friday, November 3rd / 1:55 PM

About Khaled Abdelrahman

    

Dr. Khaled Abdelrahman graduated in 2006 with a BSc in Pharmaceutical Sciences from Alexandria University (Egypt) followed by MSc in Pharmacology in the same university that was conferred in 2009. He joined the laboratory of Dr. William Cole at the University of Calgary in 2010 for his Ph.D. where he studied the molecular basis underlying altered cerebrovascular function and blood flow in type 2 diabetes. In 2015, He joined Dr. Stephen Ferguson’s laboratory in the Departments of Cellular & Molecular Medicine and Neuroscience at the University of Ottawa as a Postdoctoral Fellow to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted pharmacologically to slow neurodegeneration. He has been also studying what aspects of GPCR signaling are regulated in a sex-selective manner and how this can influence drug discovery in the area of neurodegenerative diseases.


He is also a Registered Pharmacist in Canada and held two of the most prestigious Clinician Postdoctoral Fellowships offered by Alberta Innovates and Canadian Institutes of Health Research. He received the Canadian Society of Pharmacology and Therapeutics Postdoctoral and Publication awards along with many Young Scientist Awards from the American Society for Pharmacology and Experimental Therapeutics.

    

   

Khaled Abdelrahman on the web

        

Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec

Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec


22nd GPCR Retreat Sponsored by


 

Canada Research Chairs
U of Ottawa
Dr. GPCR
Canadian Institutes of Health Research
Bristol Myers Squibb
InversAgo Pharma
Monica Seger and Family
Duke University, Dept. Cell Biology
OHRI Neurosciences Program
University of Toronto Mississauga
Domain Therapeutics NA Inc.
Otsuka Pharmaceuticals
McGill University, Dept. Pharmacol & Exp Ther
University of Toronto, Dept. of Physiology
Hotchkiss Brain Institute,University of Calgary
OHRI
Université de Montréal, VP Office
Find Therapeutics
University of Toronto, Dept. Pharmacol & Toxicol
Deep Apple
University of Illinois at Chicago (Mark Rasenick)
uOttawa, VP Research Office
American Society of Pharmacology and Experimental Therapeutics
University of Western Ontario Schulich School of Medicine & Dentistry
Heliyon
Université de Sherbrooke, Dept. Pharmacology-Physiology
Research Institute McGill Univ. Health Centre
adMare Bioinnovations
Superluminal
Université de Montréal, Faculty of Medicine
Université de Sherbrooke, Institut de Pharmacologie
Science Signaling
Montana Molecular
IRIC
uOttawa, Dept. Cellular & Molecular Medicine
uOttawa, Dept. Biochem Microbiol Immunol
uOttawa, Behavioral & Physiology Core